Los Angeles Capital Management
ALDR

Los Angeles Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Los Angeles Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-31,217
Closed -$382K – 1437
2017
Q3 		$382K Buy
+31,217
New +$325K ﹤0.01% 1085

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Los Angeles Capital Management's ALDR Position: Q4 2017 in Review

Los Angeles Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2017, closing a stake of 31,217 shares — an estimated $382K sold.

Los Angeles Capital Management first reported a position in ALDR in Q3 2017 and held it in 1 quarter. The position peaked at $382K in Q3 2017. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

  • Los Angeles Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Los Angeles Capital Management sold 31,217 Alder Biopharmaceuticals shares in Q4 2017, an estimated $382K.
  • Los Angeles Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Los Angeles Capital Management's Alder Biopharmaceuticals position peaked at $382K in Q3 2017.
  • 140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Los Angeles Capital Management's 13F filing for Q4 2017, filed 5 Feb 2018.